Trials / Completed
CompletedNCT00111618
Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
An Open Label, Randomized, Phase II Study of AS1404 in Combination With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Antisoma Research · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to confirm a safe dose of AS1404, to be given with docetaxel, and to see whether adding AS1404 and docetaxel together improves the outcome of the treatment, when compared to docetaxel alone.
Detailed description
The overall aim of this study is to determine the safety, tolerability and efficacy of AS1404 in combination with docetaxel in patients with hormone refractory metastatic prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AS1404 (DMXAA) |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2007-06-01
- Completion
- 2008-08-01
- First posted
- 2005-05-25
- Last updated
- 2009-01-30
Locations
27 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00111618. Inclusion in this directory is not an endorsement.